全球mRNA治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

mRNA療法市場預計將從2025年的215.2億美元成長到2034年的906億美元，2026年至2034年的複合年成長率為17.32%。

由於傳訊RNA技術的進步及其在治療多種疾病的潛力，全球mRNA療法市場正經歷快速成長。 mRNA療法透過將遺傳訊息傳遞給細胞，使其產生能夠預防或治療疾病的特定蛋白質。近年來，這種創新方法引起了廣泛關注，尤其是在疫苗研發領域的成功。

生技公司和研究機構正在探索基於mRNA的治療方法，用於治療方法癌症、遺傳性疾病、感染疾病等。 mRNA技術的柔軟性使科學家能夠快速設計治療方法並針對特定的疾病機制。遞送系統（例如脂質奈米顆粒）的進步也提高了基於mRNA的療法的穩定性和療效。

隨著臨床研究不斷證實mRNA療法的潛力，市場預計將持續成長。製藥公司正大力投資開發利用該技術的新治療方法。在生物技術快速發展的背景下，mRNA療法有望在下一代醫學中發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球mRNA治療市場：依應用領域分類

• 市場分析、洞察與預測
• 感染疾病
• 腫瘤學
• 罕見遺傳疾病
• 呼吸系統疾病
• 其他

第5章 全球mRNA治療市場：依類型分類

• 市場分析、洞察與預測
• 預防
• 治療

第6章：全球mRNA治療市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院和診所
• 研究機構
• 其他

第7章 全球mRNA治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Moderna Inc
  • BioNTech SE
  • CureVac NV
  • Arcturus Therapeutics Holdings Inc
  • Sanofi
  • GlaxoSmithKline Plc
  • Argos Therapeutics Inc
  • Ethris GmbH
  • Pfizer Inc
  • AstraZeneca Plc

The mRNA Therapeutics Market size is expected to reach USD 90.60 Billion in 2034 from USD 21.52 Billion (2025) growing at a CAGR of 17.32% during 2026-2034.

The global mRNA therapeutics market is experiencing rapid growth due to advancements in messenger RNA technology and its potential to treat a wide range of diseases. mRNA therapeutics work by delivering genetic instructions to cells, enabling them to produce specific proteins that can prevent or treat diseases. This innovative approach has gained significant attention in recent years due to its success in vaccine development.

Biotechnology companies and research institutions are exploring mRNA-based treatments for conditions such as cancer, genetic disorders, and infectious diseases. The flexibility of mRNA technology allows scientists to design therapies quickly and target specific disease mechanisms. Advances in delivery systems, such as lipid nanoparticles, are also improving the stability and effectiveness of mRNA therapeutics.

In the future, the market is expected to grow as clinical research continues to demonstrate the potential of mRNA-based treatments. Pharmaceutical companies are investing heavily in developing new therapeutic applications using this technology. As biotechnology innovation progresses, mRNA therapeutics are likely to become an important part of next-generation medical treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

By Type

• Prophylactic
• Therapeutic

By End-use

• Hospitals & Clinics
• Research Organizations
• Others

COMPANIES PROFILED

• Moderna Inc, BioNTech SE, CureVac NV, Arcturus Therapeutics Holdings Inc, Sanofi, GlaxoSmithKline plc, Argos Therapeutics Inc, Ethris GmbH, Pfizer Inc, AstraZeneca plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Respiratory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MRNA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MRNA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MRNA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Type
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Type
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Type
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Type
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Type
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MRNA THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Moderna Inc
  • 9.2.2 BioNTech SE
  • 9.2.3 CureVac N.V
  • 9.2.4 Arcturus Therapeutics Holdings Inc
  • 9.2.5 Sanofi
  • 9.2.6 GlaxoSmithKline Plc
  • 9.2.7 Argos Therapeutics Inc
  • 9.2.8 Ethris GmbH
  • 9.2.9 Pfizer Inc
  • 9.2.10 AstraZeneca Plc